A straightforward statistical explanation is provided to show how differences between assay methods can affect the distribution of the multiples of the median (MoM 
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It is accepted practice to report maternal serum alpha-fetoprotein (MSAFP) measurements as multiples of the laboratory's normal population median concentration for the relevant gestational age for between-laboratories comparisons of the distribution of results. This mode of expressing aipha-fetoprotein data is a consequence of exemplary work investigating the relationship between high concentrations of MSAFP and neural tube defects published in the late 1970s and early '80s by the U.K. collaborative study on aipha-fetoprotein in relation to neural-tube defects (1, 2 (3) (4) (5) (6) . These discrepancies have been attributed to population differences, method imprecision, inappropriate quality control, and kit problems. Here we describe some currently unappreciated fundamental probabilistic concepts related to the impact of assay method differences on the distribution of the MoM, using MSAFP as an example. We illustrate the consequences of these concepts on the apparent sensitivity and specificity of an assay method, on the calculation of risks (which has been recommended for MSAFP screening for Down's syndrome), and on the use of published estimates based on MoM data.
Theory
We assume the functional relationship between two different methods for measuring an analyte can be described by a linear equation: y = a + bx, where x refers to values by one method, y refers to values by another method, a is the constant bias, and b is the proportional bias between the methods. This is the recommended model for method comparison analyses in laboratory medicine (7). If we let M and M denote the median concentrations for method Y and X, respectively, then y = a + bx implies that M = a + bM, and the relationship between the multiples of the medians willbe y a
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MoM, by a log-normal distribution (8) .
Results
To produce the graphs that follow, we sought a reasonable value for the upper limit for aIM1 An illustration with MSAFP data. In 1988, the MSAFP commercial assay used at our institution was changed. During our evaluation process of the new assay, we performed a method comparison. Figure 6 shows the resulting data and estimated functional relationship. Inclusion of a quadratic term was found to be statistically significant. The positive constant bias between the Tables 1 and 2 The conclusions drawn from these models or any other model that reasonably describes a set of method-comparison data would be similar to our conclusions because they would produce functional relationships that are similar over the majority of the range of concentrations.
From equation 1, the degree of difference between
MoM distributions depends on the magnitude of aIM,, which depends on the magnitude of its numerator, the Tables 1 and 2 .
The results presented here predict that a difference between the distributions of MoM, and MoM, in the fraction of MoMs <0.5 will be greater than the difference in the fraction of MoMs >2.5 (Figure 3) , consistent with reports in the MSAFP literature.
Although other factors such as population differences or precision differences can also contribute to the difference in the fraction of MoMs <0.5, constant bias between MSAFP assays can, in rare circumstances, account for a range of 3 A constant bias between assay methods does not affect the diagnostic efficacy of the MoMs by either method.
The transformation represented
by equation 1 applies to both affected and unaffected populations, so that the relative separation between the populations (with respect to their dispersions) is unchanged. However, the sensitivity and specificity associated with a given MoM such as 0.5 will not be the same for both methods. Rather, the sensitivity and specificity associated with 0.5 by one mthod will be associated with a different MoM, say 0.6, by the other method (Figure 4) . Because the cutoffs of 0.5 and 2.5 are so commonly accepted in the MSAFP field, in most cases centers will choose to operate at different true-positive and false-positive rates rather than use cutoffs different from 0.5 and 2.5.
Current recommendations
for MSAFP interpretation suggest that the risk of carrying an affected fetus should be reported in addition to the MoM value (16) . If the distributions for affected and unaffected pregnancies in a given population are established separately for each MSAFP method, then the likelihood ratios obtained will be consistent between methods, and the fraction of the population above or below a given risk will be comparable. That is, using risk cutoffs eliminates discrepancies due to method-comparison differences encountered when fixed MoM cutoffs are used. On the other hand, if a center uses published estimates for the distributions of the affected and unaffected populations, and a constant bias exists between the center's MSAFP method and the method used to estimate the population-based estimates, then the fraction of risks above or below a given risk value will differ between the two centers in the same way that the fraction above or below a given MoM will differ.
illustrating the impact of assay method differences by the use of MSAFP data from our institution in Tables 1  and 2 is not intended to suggest that these data or the degree of change in the MoM distributions shown in these Tables is typical. In fact, these data possibly reflect an extreme case. However, the methods and results reported here do not depend on any particular assay or procedure, and the data obtained at our institution effectively demonstrate the concepts. Although our discussion has focused on the consequences of differences between MSAFP assay methods used in different laboratories, these data also emphasize that the same concepts apply when changing assays in a laboratory, or even when changes occur within an assay kit used in a laboratory that result in a method-comparison difference.
In the evaluation reported here, we did not account for either true population differences between centers, precision differences or differences in the lower limits of accuracy between assay methods, or any of the factors that might affect the way a center calculates its MoM values (17) . Additionally, we did not consider data adjustments to the MoM that are frequently made for maternal weight, race, and diabetes, based on published adjustment factors estimated from MoM data. The degree of impact that assay differences might have on the estimates of various adjustment factors has not been studied.
We have tried to convey some important and unappreciated probabilistic results with respect to the reporting of data as MoMs. Appreciating these concepts is important not only for laboratories involved in ongoing screening programs involving MSAFP, but also for interpretation of the body of MSAFP literature that has appeared over the last 13 years and for understanding the consequences of reporting results as MoMs for other analytes, such as human choriogonadotropin and unconjugated estriol.
